BEIJING, May 20, 2016 /PRNewswire/ -- Sinovac Biotech Ltd.
(Nasdaq: SVA), a leading provider of biopharmaceutical products in
China, today announced that it
will release its unaudited financial results for the first quarter,
ended March 31, 2016, after the
market closes on Thursday, May 26,
2016. The Company will host a conference call on Friday, May 27, 2016, at 8:00 a.m. EDT (Friday, May
27, 2016 at 8:00 p.m. China
Standard Time) to review the Company's financial results and
provide an update on recent corporate developments.
To access the conference call, please dial 1-877-407-9039
(USA) or 1-201-689-8470
(International). A replay of the call will be available after the
earnings call through June 10, 2016.
To access the replay, please dial 1-877-870-5176 (USA) or 1-858-384-5517 (International) and
reference the replay pin number 13638158.
A live audio webcast of the call will also be available on the
Investor Relations section of the Company's website at
www.sinovac.com. A webcast replay will be available on the
Company's website for 30 days following the call.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacturing, and
commercialization of vaccines that protect against human infectious
diseases. Sinovac's product portfolio includes vaccines against
hepatitis A and B, seasonal influenza, H5N1 pandemic influenza
(avian flu), H1N1 influenza (swine flu), mumps and canine rabies.
In 2009, Sinovac was the first company worldwide to receive
approval for its H1N1 influenza vaccine, which it has supplied to
the Chinese Government's vaccination campaign and stockpiling
program. The Company is also the only supplier of the H5N1 pandemic
influenza vaccine to the government stockpiling program. Sinovac's
newly developed innovative vaccine against HFMD caused by EV71
entered the commercialization production phase and will be launched into the market
by the end of first half of 2016. The Company is currently
developing a number of new products including a Sabin-strain
inactivated polio vaccine, pneumococcal polysaccharides vaccine,
pneumococcal conjugate vaccine and varicella vaccine. Sinovac
primarily sells its vaccines in China, while also exploring growth
opportunities in international markets. The Company has exported
select vaccines to Mexico,
Mongolia, Nepal, Tajikistan, Bangladesh, Chile and the
Philippines, and was recently granted a license to
commercialize its influenza vaccine in Guatemala. For more information, please visit
the Company's website at www.sinovac.com.
Contact
Sinovac Biotech Ltd.
Helen Yang
Tel: +86-10-8279-9871
Email: ir@sinovac.com
ICR Inc.
Bill Zima
U.S: 1-646-308-1707
Email: william.zima@icrinc.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sinovac-to-host-conference-call-to-report-first-quarter-of-2016-unaudited-financial-results-300272294.html
SOURCE Sinovac Biotech Co., Ltd.